Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach
Abstract Background Rabies, a potentially lethal virus, affects more than 150 countries. Although the rabies vaccine and immunoglobulin have been available since 1908, Bangladesh is new to vaccine manufacturing. We checked the quality of the local manufacturing rabies vaccine for substandard. Method...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.1198 |
| _version_ | 1797292147269959680 |
|---|---|
| author | Fahima Akter Md. Shamimuzzaman |
| author_facet | Fahima Akter Md. Shamimuzzaman |
| author_sort | Fahima Akter |
| collection | DOAJ |
| description | Abstract Background Rabies, a potentially lethal virus, affects more than 150 countries. Although the rabies vaccine and immunoglobulin have been available since 1908, Bangladesh is new to vaccine manufacturing. We checked the quality of the local manufacturing rabies vaccine for substandard. Methods The potency and immunogenicity of 20 vaccines were analyzed by three in vivo and in vitro methods from March 2020 to May 2023. Single radial immunodiffusion, fluorescent antibody virus neutralization, and national institutes of health tests were carried out to evaluate the vaccine's efficacy to provide sufficient protection against the rabies virus. Results The potency of the rabies vaccine was determined by the in vitro SRID method by measuring glycoprotein content. An average of 16 articles from each batch was calculated. The minimum and maximum average mean values of the 20 batches were 5.058 and 5.346, respectively. The variance was calculated at 0.00566. We found a coefficient of variation (CV) between 9.36% and 14.80%. The 100% sample was satisfactory, as these samples had a potency of over 2.5 IU/mL. To observe immunogenicity, we applied the FAVN method for determining antibody titers. An average of 16 articles from every batch were counted to quantify antibody titers. The mean quantity of antibody titers ranged from 2.389 to 3.3875. The CV was slightly lower because of the dispersion of the data. At last, we performed an in vivo method, the NIH test method, to determine potency based on mortality rate. We found a mean value of 4.777 IU/SHD with a standard deviation of 1.13 IU/SHD. All 20 batches were found 100% satisfactory in the NIH test. Conclusion The study implies that the rabies human vaccines manufactured in Bangladesh are potent enough to provide sufficient immunogenicity. Our research is warranted testimony for healthcare providers who work to extirpate rabies. |
| first_indexed | 2024-03-07T19:47:33Z |
| format | Article |
| id | doaj.art-a23123d1b7e546249c9884c40d304770 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-03-07T19:47:33Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-a23123d1b7e546249c9884c40d3047702024-02-28T18:18:31ZengWileyImmunity, Inflammation and Disease2050-45272024-02-01122n/an/a10.1002/iid3.1198Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approachFahima Akter0Md. Shamimuzzaman1Department of Microbiology and Hygiene Bangladesh Agricultural University Mymensingh BangladeshDepartment of Microbiology Jashore University of Science and Technology Jashore BangladeshAbstract Background Rabies, a potentially lethal virus, affects more than 150 countries. Although the rabies vaccine and immunoglobulin have been available since 1908, Bangladesh is new to vaccine manufacturing. We checked the quality of the local manufacturing rabies vaccine for substandard. Methods The potency and immunogenicity of 20 vaccines were analyzed by three in vivo and in vitro methods from March 2020 to May 2023. Single radial immunodiffusion, fluorescent antibody virus neutralization, and national institutes of health tests were carried out to evaluate the vaccine's efficacy to provide sufficient protection against the rabies virus. Results The potency of the rabies vaccine was determined by the in vitro SRID method by measuring glycoprotein content. An average of 16 articles from each batch was calculated. The minimum and maximum average mean values of the 20 batches were 5.058 and 5.346, respectively. The variance was calculated at 0.00566. We found a coefficient of variation (CV) between 9.36% and 14.80%. The 100% sample was satisfactory, as these samples had a potency of over 2.5 IU/mL. To observe immunogenicity, we applied the FAVN method for determining antibody titers. An average of 16 articles from every batch were counted to quantify antibody titers. The mean quantity of antibody titers ranged from 2.389 to 3.3875. The CV was slightly lower because of the dispersion of the data. At last, we performed an in vivo method, the NIH test method, to determine potency based on mortality rate. We found a mean value of 4.777 IU/SHD with a standard deviation of 1.13 IU/SHD. All 20 batches were found 100% satisfactory in the NIH test. Conclusion The study implies that the rabies human vaccines manufactured in Bangladesh are potent enough to provide sufficient immunogenicity. Our research is warranted testimony for healthcare providers who work to extirpate rabies.https://doi.org/10.1002/iid3.1198FAVNimmunogenicityin vivo and in vitroNIHrabies vaccineSRID |
| spellingShingle | Fahima Akter Md. Shamimuzzaman Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach Immunity, Inflammation and Disease FAVN immunogenicity in vivo and in vitro NIH rabies vaccine SRID |
| title | Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach |
| title_full | Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach |
| title_fullStr | Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach |
| title_full_unstemmed | Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach |
| title_short | Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach |
| title_sort | potency immunogenicity and efficacy of rabies vaccine in vitro and in vivo approach |
| topic | FAVN immunogenicity in vivo and in vitro NIH rabies vaccine SRID |
| url | https://doi.org/10.1002/iid3.1198 |
| work_keys_str_mv | AT fahimaakter potencyimmunogenicityandefficacyofrabiesvaccineinvitroandinvivoapproach AT mdshamimuzzaman potencyimmunogenicityandefficacyofrabiesvaccineinvitroandinvivoapproach |